Multitarget AD-IN-6 (Compound 39) is a multi-target inhibitor, with an IC50 of 15.54 µM against human PDE4B, 15.15 µM against human PDE7A, 8.39 µM against human PDE3A, and a Kd of 37.7 µM against human CHIT1. Multitarget AD-IN-6 acts as a TRPA1 antagonist, reduces the level of the NLRP3 inflammasome multiprotein complex to inhibit its activation, while inhibiting PDE4B, PDE7A and CHIT1, and decreasing the phosphorylation of NF-kappaB. Multitarget AD-IN-6 improves the pathology of elastase-induced emphysema in mice. Multitarget AD-IN-6 is applicable for the research of chronic obstructive pulmonary disease[1].
